Assessment of recent evidence for the management of patients with systemic sclerosis-associated interstitial lung disease: a systematic review Source: ERJ Open Res, 7 (1) 00235-2020; 10.1183/23120541.00235-2020 Year: 2021
The global microRNA profile of idiopathic pulmonary fibrosis Source: Annual Congress 2010 - Lung cancer, idiopathic pulmonary fibrosis and sarcoidosis: the genetic approach Year: 2010
Relationship between MIF and cellular pattern in BAL of patients with sarcoidosis, systemic sclerosis, idiopathic pulmonary fibrosis Source: Eur Respir J 2003; 22: Suppl. 45, 377s Year: 2003
The clinical efficacy of pulmonary hypertension-specific agents in idiopathic pulmonary fibrosis: A systematic review and meta-analysis Source: International Congress 2019 – Treatment and prognosis of idiopathic interstitial pneumonia Year: 2019
Response to PAH specific therapy in systemic sclerosis patients with extensive parenchymal changes and pulmonary hypertension Source: Virtual Congress 2020 – Pulmonary hypertension in lung diseases Year: 2020
IGFBP-2: a new pathway in systemic sclerosis associated interstitial lung disease Source: International Congress 2019 – Connective tissue disease-associated interstitial lung disease and hypersensitivity pneumonitis: what’s new? Year: 2019
Anti-a-enolase antibodies in systemic sclerosis identify a subset of patients with diffuse cutaneous sclerosis and interstitial lung disease Source: Annual Congress 2008 - Interstitial lung disease in systemic and vascular disorders Year: 2008
Comorbidities in idiopathic pulmonary fibrosis patients: a systematic literature review Source: Eur Respir J 2015; 46: 1113-1130 Year: 2015
Longitudinal functional evaluation of interstitial lung disease in systemic sclerosis Source: Virtual Congress 2020 – Diagnostic and prognostic markers for disease-associated interstitial lung disease and hypersensitivity pneumonitis Year: 2020
Auto-antibody subsets and extent of pulmonary fibrosis in systemic sclerosis (SSc) Source: Eur Respir J 2005; 26: Suppl. 49, 202s Year: 2005
Prognosis of idiopathic pulmonary fibrosis without anti-fibrotic therapy: a systematic review Source: Eur Respir Rev, 29 (157) 190158; 10.1183/16000617.0158-2019 Year: 2020
Two sides of the same coin? A review of the similarities and differences between idiopathic pulmonary fibrosis and rheumatoid arthritis-associated interstitial lung disease Source: Eur Respir J, 57 (5) 2002533; 10.1183/13993003.02533-2020 Year: 2021
The clinical relevance of autoimmunity in idiopathic pulmonary fibrosis Source: Annual Congress 2012 - Diffuse parenchymal lung disease II Year: 2012
Pulmonary hypertension in systemic sclerosis: different phenotypes Source: Eur Respir Rev, 26 (145) 170056; 10.1183/16000617.0056-2017 Year: 2017
Clinical feature of systemic sclerosis associated with pulmonary hypertension: results of one center study Source: Annual Congress 2008 - Pulmonary hypertension I Year: 2008
Clinical characteristics of interstitial lung fibrosis in progressive systemic sclerosis Source: Eur Respir J 2006; 28: Suppl. 50, 95s Year: 2006
Pulmonary function tests as outcomes for systemic sclerosis interstitial lung disease Source: Eur Respir Rev, 27 (148) 170102; 10.1183/16000617.0102-2017 Year: 2018
The natural course of systemic sclerosis patients with interstitial lung involvement Source: Eur Respir J 2005; 26: Suppl. 49, 336s Year: 2005
Idiopathic pulmonary fibrosis: multiple causes and multiple mechanisms? Source: Eur Respir J 2007; 30: 835-839 Year: 2007
Does delay in review of newly-diagnosed idiopathic pulmonary fibrosis (IPF) worsen outcomes? Source: International Congress 2018 – News on the diagnosis of idiopathic interstitial pneumonia Year: 2018